论文部分内容阅读
目的观察孟鲁司特预防婴幼儿毛细支气管炎后反复喘息的临床疗效与安全性。方法将本院86例门诊及住院的毛细支气管炎痊愈后患儿随机分成2组,治疗组毛细支气管炎痊愈后持续口服孟鲁司特4mg,qn,3mo;对照组不采取干预。观察2组在3mo内,出现喘息的病例数。结果治疗组出现喘息次数明显减少,治疗组喘息发生率为10%,对照组喘息发生率为32%。2组比较差异有统计学意义(P<0.01)。治疗组2例出现不良反应。结论孟鲁司特对预防毛细支气管炎后婴幼儿反复喘息有较好效果,且无严重不良反应。
Objective To observe the clinical efficacy and safety of Montelukast in the prevention of recurrent wheezing after infantile bronchiolitis. Methods 86 cases of hospitalized patients and hospitalized patients with bronchiolitis were randomly divided into two groups. The patients in the treatment group were treated with montelukast 4mg qn for 3 months after the cure, and the control group did not take any intervention. Two groups were observed within 3mo, the number of wheezing cases. Results The number of wheezing in the treatment group decreased significantly, the incidence of wheezing in the treatment group was 10%, and the incidence of wheezing in the control group was 32%. The difference between the two groups was statistically significant (P <0.01). Two patients in the treatment group had adverse reactions. Conclusion Montelukast has good effect on repeated wheezing after preventing bronchiolitis, and no serious side effects.